HRP20150173T1 - Oksazolom supstituirani indazoli kao inhibitori pi3-kinaze - Google Patents
Oksazolom supstituirani indazoli kao inhibitori pi3-kinaze Download PDFInfo
- Publication number
- HRP20150173T1 HRP20150173T1 HRP20150173TT HRP20150173T HRP20150173T1 HR P20150173 T1 HRP20150173 T1 HR P20150173T1 HR P20150173T T HRP20150173T T HR P20150173TT HR P20150173 T HRP20150173 T HR P20150173T HR P20150173 T1 HRP20150173 T1 HR P20150173T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- oxazol
- salt
- methyl
- pyridinyl
- Prior art date
Links
- 150000002473 indoazoles Chemical class 0.000 title 1
- 125000002971 oxazolyl group Chemical group 0.000 title 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 17
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 7
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 6
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 206010052779 Transplant rejections Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical group 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- NLUPPCTVKHDVIQ-GASCZTMLSA-N n-[5-[4-[5-[[(2r,6s)-2,6-dimethylmorpholin-4-yl]methyl]-1,3-oxazol-2-yl]-1h-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide Chemical compound C1=C(NS(C)(=O)=O)C(OC)=NC=C1C1=CC(C=2OC(CN3C[C@@H](C)O[C@@H](C)C3)=CN=2)=C(C=NN2)C2=C1 NLUPPCTVKHDVIQ-GASCZTMLSA-N 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 208000004852 Lung Injury Diseases 0.000 claims 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 231100000515 lung injury Toxicity 0.000 claims 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000019100 sperm motility Effects 0.000 claims 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- HALNPIXAKRGUTD-UHFFFAOYSA-N 2,4-difluoro-n-[2-methoxy-5-[4-[5-[(4-propan-2-ylpiperazin-1-yl)methyl]-1,3-oxazol-2-yl]-1h-indazol-6-yl]pyridin-3-yl]benzenesulfonamide Chemical compound COC1=NC=C(C=2C=C3NN=CC3=C(C=3OC(CN4CCN(CC4)C(C)C)=CN=3)C=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F HALNPIXAKRGUTD-UHFFFAOYSA-N 0.000 claims 1
- 201000002909 Aspergillosis Diseases 0.000 claims 1
- 208000036641 Aspergillus infections Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- LWCKBXWOANSAIZ-UHFFFAOYSA-N n-[2-methoxy-5-[4-[5-[(4-propan-2-ylpiperazin-1-yl)methyl]-1,3-oxazol-2-yl]-1h-indazol-6-yl]pyridin-3-yl]methanesulfonamide Chemical compound C1=C(NS(C)(=O)=O)C(OC)=NC=C1C1=CC(C=2OC(CN3CCN(CC3)C(C)C)=CN=2)=C(C=NN2)C2=C1 LWCKBXWOANSAIZ-UHFFFAOYSA-N 0.000 claims 1
- NLUPPCTVKHDVIQ-HUUCEWRRSA-N n-[5-[4-[5-[[(2r,6r)-2,6-dimethylmorpholin-4-yl]methyl]-1,3-oxazol-2-yl]-1h-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide Chemical compound C1=C(NS(C)(=O)=O)C(OC)=NC=C1C1=CC(C=2OC(CN3C[C@@H](C)O[C@H](C)C3)=CN=2)=C(C=NN2)C2=C1 NLUPPCTVKHDVIQ-HUUCEWRRSA-N 0.000 claims 1
- XKTYUDPOFFQXQD-CALCHBBNSA-N n-[5-[4-[5-[[(2r,6s)-2,6-dimethylmorpholin-4-yl]methyl]-1,3-oxazol-2-yl]-1h-indazol-6-yl]-2-methoxypyridin-3-yl]-2,4-difluorobenzenesulfonamide Chemical compound COC1=NC=C(C=2C=C3NN=CC3=C(C=3OC(CN4C[C@@H](C)O[C@@H](C)C4)=CN=3)C=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F XKTYUDPOFFQXQD-CALCHBBNSA-N 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Claims (23)
1. Spoj of formula (I):
[image]
,
naznačen time što
R1 je 9- ili 10-eročlani biciklički heteroaril, gdje 9- ili 10-eročlani biciklički heteroaril sadrži od jednog do tri heteroatoma, koje se neovisno bira između kisika i dušika i izborno je supstituiran s C1-6alkilom, C3-6cikloalkilom, halogenom, -CN ili -NHSO2R5, ili piridinil, izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između C1-6alkila, -OR6, halogena i -NHSO2R7;
R2 i R3, zajedno s atomom dušika s kojim su spojeni, su tako vezani da tvore 6- ili 7-eročlani heterociklil, gdje 6- ili 7-eročlani heterociklil izborno sadrži atom kisika ili dodatni atom dušika i izborno je supstituiran s jednim ili dva supstituenta, koje se neovisno bira između C1-6alkila;
R4 je vodik ili metil;
R6 je vodik ili C1-4alkil; i
svaki od R5 i R7 je neovisno C1-6alkil, ili fenil, izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između halogena;
ili njegova sol.
2. Spoj u skladu s patentni zahtjevom 1, ili njegova sol, naznačen time što je R1 9-eročlani biciklički heteroaril, gdje 9-eročlani biciklički heteroaril sadrži jedan ili dva atoma dušika, ili piridinil, izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između -OR6 i -NHSO2R7.
3. Spoj u skladu s patentni zahtjevom 1 ili patentni zahtjev 2, ili njegova sol, naznačen time što je R1 indolil.
4. Spoj u skladu s patentni zahtjevom 1 ili patentni zahtjev 2, ili njegova sol, naznačen time što je R1 piridinil, izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između -OR6 i -NHSO2R7.
5. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, ili njegova sol, naznačen time što su R2 i R3, zajedno s atomom dušika s kojim su spojeni, tako vezani da tvore 6-eročlani heterociklil, gdje 6-eročlani heterociklil izborno sadrži atom kisika ili dodatni atom dušika i izborno je supstituiran s jednim ili dva supstituenta, koje se neovisno bira između C1-6alkila.
6. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, ili njegova sol, naznačen time što su R2 i R3, zajedno s atomom dušika s kojim su spojeni, tako vezani da tvore 6-eročlani heterociklil, gdje 6-eročlani heterociklil sadrži atom kisika i izborno je supstituiran s jednim ili dva supstituenta, koje se neovisno bira između C1-4alkila.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5, ili njegova sol, naznačen time što su R2 i R3, zajedno s atomom dušika s kojim su spojeni, tako vezani da tvore 6-eročlani heterociklil, gdje 6-eročlani heterociklil sadrži dodatni atom dušika i izborno je supstituiran s C1-4alkilom.
8. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, ili njegova sol, naznačen time što je R4 vodik.
9. Spoj u skladu s patentni zahtjevom 1, naznačen time što je:
N-[5-[4-(5-{[(2R,6S)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1H-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamid;
N-[5-[4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1H-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamid;
N-[5-[4-(5-{[(2R,6S)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1H-indazol-6-il]-2-(metiloksi)-3-piridinil]-2,4-difluorbenzensulfonamid;
2,4-difluor-N-[5-[4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1H-indazol-6-il]-2-(metiloksi)-3-piridinil]benzensulfonamid;
4-((5-{[(2R,6S)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-6-(1H-indol-4-il)-1H-indazol;
6-((1H-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1H-indazol;
6-((1H-indol-4-il)-4-[5-(4-morfolinilmetil)-1,3-oksazol-2-il]-1H-indazol;
N-[5-[4-(5-{[(2R,6R)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1H-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamid;
6-((1H-indol-4-il)-4-[5-(1-piperazinilmetil)-1,3-oksazol-2-il]-1H-indazol; ili
njihove soli.
10. Spoj u skladu s patentni zahtjevom 1, naznačen time što je:
N-[5-[4-(5-{[(2R,6S)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1H-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamid
[image]
,
ili njegova sol.
11. Spoj u skladu s patentni zahtjevom 1, naznačen time što je:
6-((1H-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1H-indazol
[image]
,
ili njegova sol.
12. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je u obliku svoje farmaceutski prihvatljive soli.
13. Spoj u skladu s patentni zahtjevom 11, naznačen time što je u obliku soli s jantarnom kiselinom.
14. Spoj u skladu s patentni zahtjevom 1, naznačen time što je:
N-[5-[4-(5-{[(2R,6S)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1H-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamid
[image]
.
15. Spoj u skladu s patentni zahtjevom 1, naznačen time što je:
6-((1H-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1H-indazol
[image]
.
16. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 11, ili njegovu farmaceutski prihvatljivu sol, kao i jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
17. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u medicinskoj terapiji.
18. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju poremećaja uzrokovanog neodgovarajućom aktivnošću PI3-kinaze.
19. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 11, ili njegove farmaceutski prihvatljive soli, naznačena time što je spoj namijenjen proizvodnji medikamenta namijenjenog upotrebi u liječenju poremećaja uzrokovanog neodgovarajućom aktivnošću PI3-kinaze.
20. Spoj namijenjen upotrebi u skladu s patentni zahtjevom 18, naznačen time što je poremećaj uzrokovan neodgovarajućom aktivnošću PI3-kinaze respiratorna bolest, virusna infekcija, nevirusna respiratorna infekcija, alergijska bolest, autoimuna bolest, upalni poremećaj, kardiovaskularna bolest, hematološki zloćudni tumor, neurodegenerativna bolest, pankreatitis, multiorganska insuficijencija, bubrežna bolest, agregacija trombocita, rak, pokretljivost sjemena, odbacivanje transplantata, odbacivanje presatka, ozljeda pluća ili bol.
21. Spoj namijenjen upotrebi u skladu s patentni zahtjevom 18, naznačen time što je poremećaj uzrokovan neodgovarajućom aktivnošću PI3-kinaze astma, kronična opstruktivna plućna bolest (COPD), idiopatska fibroza pluća (IPF), virusne infekcije dišnog sustava, virusna egzacerbacija respiratornih bolesti, aspergiloza, lišmenijaza, alergijski rinitis, atopični dermatitis, reumatoidni artritis, multipla skleroza, upalna bolest crijeva, tromboza, ateroskleroza, hematološki zloćudni tumor, neurodegenerativna bolest, pankreatitis, multiorganska insuficijencija, bubrežna bolest, agregacija trombocita, rak, pokretljivost sjemena, odbacivanje transplantata, odbacivanje presatka, ozljeda pluća, bol povezana s reumatoidnim artritisom ili osteoartritisom, bol u leđima, opća upalna bol, post hepatski neuralgija, dijabetična neuropatija, upalna neuropatska bol (trauma), trigeminalna neuralgija ili centralna bol.
22. Spoj namijenjen upotrebi u skladu s patentni zahtjevom 18, naznačen time što je poremećaj uzrokovan neodgovarajućom aktivnošću PI3-kinaze astma.
23. Spoj namijenjen upotrebi u skladu s patentni zahtjevom 18, naznačen time što je poremećaj uzrokovan neodgovarajućom aktivnošću PI3-kinaze COPD.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17403309P | 2009-04-30 | 2009-04-30 | |
PCT/EP2010/055666 WO2010125082A1 (en) | 2009-04-30 | 2010-04-28 | Oxazole substituted indazoles as pi3-kinase inhibitors |
EP10714892.6A EP2424864B1 (en) | 2009-04-30 | 2010-04-28 | Oxazole substituted indazoles as pi3-kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20150173T1 true HRP20150173T1 (hr) | 2015-05-22 |
Family
ID=42225106
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150173TT HRP20150173T1 (hr) | 2009-04-30 | 2015-02-16 | Oksazolom supstituirani indazoli kao inhibitori pi3-kinaze |
HRP20171450TT HRP20171450T1 (hr) | 2009-04-30 | 2017-09-27 | Indazoli supstituirani oksazolom kao inhibitori pi3-kinaze |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171450TT HRP20171450T1 (hr) | 2009-04-30 | 2017-09-27 | Indazoli supstituirani oksazolom kao inhibitori pi3-kinaze |
Country Status (40)
Country | Link |
---|---|
US (14) | US20120046286A1 (hr) |
EP (3) | EP3260453B1 (hr) |
JP (1) | JP5570589B2 (hr) |
KR (2) | KR101771193B1 (hr) |
CN (1) | CN102459253B (hr) |
AR (2) | AR076435A1 (hr) |
AU (1) | AU2010243613B2 (hr) |
BR (1) | BRPI1016219B8 (hr) |
CA (1) | CA2759476C (hr) |
CL (1) | CL2011002706A1 (hr) |
CO (1) | CO6390057A2 (hr) |
CR (1) | CR20110603A (hr) |
CY (1) | CY1119515T1 (hr) |
DK (2) | DK2424864T3 (hr) |
DO (1) | DOP2011000328A (hr) |
EA (1) | EA021056B1 (hr) |
ES (3) | ES2876933T3 (hr) |
HK (2) | HK1165801A1 (hr) |
HR (2) | HRP20150173T1 (hr) |
HU (1) | HUE034724T2 (hr) |
IL (1) | IL215803A (hr) |
JO (1) | JO3025B1 (hr) |
LT (1) | LT2899191T (hr) |
MA (1) | MA33304B1 (hr) |
ME (2) | ME02900B (hr) |
MX (1) | MX2011011534A (hr) |
MY (1) | MY160454A (hr) |
NZ (1) | NZ596071A (hr) |
PE (1) | PE20120321A1 (hr) |
PL (2) | PL2899191T3 (hr) |
PT (2) | PT2899191T (hr) |
RS (2) | RS56433B1 (hr) |
SG (2) | SG10201401881QA (hr) |
SI (2) | SI2424864T1 (hr) |
SM (1) | SMT201500043B (hr) |
TW (3) | TWI466884B (hr) |
UA (1) | UA101098C2 (hr) |
UY (1) | UY32585A (hr) |
WO (1) | WO2010125082A1 (hr) |
ZA (1) | ZA201107878B (hr) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009147189A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
EP2300437B1 (en) | 2008-06-05 | 2013-11-20 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
EP2280959B1 (en) | 2008-06-05 | 2012-04-04 | Glaxo Group Limited | 4-amino-indazoles |
EP2406255B1 (en) | 2009-03-09 | 2015-04-29 | Glaxo Group Limited | 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases |
CA2759476C (en) | 2009-04-30 | 2018-10-09 | Julie Nicole Hamblin | Novel compounds |
CN102372675B (zh) * | 2010-08-14 | 2013-12-18 | 王娜 | 6-氯-4-碘吲唑及其制备方法与应用 |
US9102668B2 (en) | 2010-09-08 | 2015-08-11 | Glaxo Group Limited | Polymorphs and salts |
EP2614058B1 (en) | 2010-09-08 | 2015-07-08 | GlaxoSmithKline Intellectual Property Development Limited | POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE |
US9326987B2 (en) | 2010-09-08 | 2016-05-03 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
JP6063870B2 (ja) * | 2010-11-08 | 2017-01-18 | ライセラ・コーポレイション | RORγ活性の阻害用のN−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療 |
DK2790705T3 (en) | 2011-12-15 | 2018-03-12 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
US9394315B2 (en) | 2012-05-08 | 2016-07-19 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US9657033B2 (en) | 2012-05-08 | 2017-05-23 | Lycera Corporation | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease |
US9284309B2 (en) | 2012-07-16 | 2016-03-15 | Neuropore Therapies, Inc. | Di- and tri-heteroaryl derivatives as inhibitors of protein aggregation |
EP2914260A1 (en) | 2012-10-31 | 2015-09-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
WO2014098232A1 (ja) * | 2012-12-21 | 2014-06-26 | Yamashita Chikamasa | Pi3キナーゼ阻害剤を含む医薬組成物、ビタミンd受容体に作用する化合物を含む医薬組成物、凍結乾燥組成物、凍結乾燥組成物の製造方法、及び経肺投与用医薬組成物 |
JP2016537327A (ja) * | 2013-10-17 | 2016-12-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 呼吸器疾患の治療のためのpi3k阻害剤 |
WO2015055691A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
US9809561B2 (en) | 2013-12-20 | 2017-11-07 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
WO2015095792A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease |
JP2017503838A (ja) * | 2014-01-24 | 2017-02-02 | アッヴィ・インコーポレイテッド | 6−フェニル−または6−(ピリジン−3−イル)インダゾール誘導体および使用方法 |
US10532088B2 (en) | 2014-02-27 | 2020-01-14 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
US11806266B2 (en) | 2014-03-19 | 2023-11-07 | Purewick Corporation | Apparatus and methods for receiving discharged urine |
AU2015256190B2 (en) | 2014-05-05 | 2019-08-15 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
US10189777B2 (en) | 2014-05-05 | 2019-01-29 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease |
US9127069B1 (en) * | 2014-06-11 | 2015-09-08 | Antecip Bioventures LLC | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
CN104086538B (zh) * | 2014-06-13 | 2016-07-06 | 南京药石科技股份有限公司 | 一种pi3k激酶抑制剂的中间体及其制备方法与应用 |
WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
CA2975997A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof |
CA2982847A1 (en) | 2015-05-05 | 2016-11-10 | Lycera Corporation | Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease |
GB201509492D0 (en) * | 2015-06-02 | 2015-07-15 | Glaxosmithkline Ip Dev Ltd | Novel processes |
KR20180025894A (ko) | 2015-06-11 | 2018-03-09 | 라이세라 코퍼레이션 | Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료 |
EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
MX2018005004A (es) | 2015-10-27 | 2018-09-12 | Merck Sharp & Dohme | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. |
JP2018531957A (ja) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | RORγT阻害薬としての置換二環式ピラゾール化合物及びその使用 |
MX2018008272A (es) * | 2016-01-14 | 2019-01-31 | Handok Inc | Compuestos antagonizantes del receptor a3 de la adenosina, metodo para prepararlos y uso medico de los mismos. |
EP3497100A1 (en) * | 2016-08-08 | 2019-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds |
CA3098570C (en) | 2018-05-01 | 2023-09-26 | Purewick Corporation | Fluid collection devices, related systems, and related methods |
US11801186B2 (en) | 2020-09-10 | 2023-10-31 | Purewick Corporation | Urine storage container handle and lid accessories |
CN116438200A (zh) | 2020-09-10 | 2023-07-14 | 普雷西里克斯公司 | 针对fap的抗体片段 |
CN115335012A (zh) | 2021-01-19 | 2022-11-11 | 普利维克公司 | 可变配合式流体收集设备、系统和方法 |
WO2022182385A1 (en) | 2021-02-26 | 2022-09-01 | Purewick Corporation | Fluid collection devices having a sump between a tube opening and a barrier, and related systems and methods |
WO2023147603A2 (en) * | 2022-01-31 | 2023-08-03 | Intra-Cellular Therapies, Inc. | Salt crystals |
WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Family Cites Families (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
MX9301943A (es) | 1992-04-02 | 1994-08-31 | Smithkline Beecham Corp | Compuestos. |
AU692892B2 (en) | 1994-06-15 | 1998-06-18 | Wellcome Foundation Limited, The | Enzyme inhibitors |
DK0820279T3 (da) | 1995-04-14 | 2002-10-07 | Smithkline Beecham Corp | Dosisudmålende inhalator til Albuterol |
US5821243A (en) | 1996-07-22 | 1998-10-13 | Viropharma Incorporated | Compounds compositions and methods for treating influenza |
MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
TW533865U (en) | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
AU3328499A (en) | 1998-03-14 | 1999-10-11 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone pde iii/iv inhibitors |
GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
EP1175422A2 (en) | 1999-05-04 | 2002-01-30 | Ligand Pharmaceuticals Incorporated | Tetracyclic progesterone receptor modulator compounds and methods |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
AR032361A1 (es) | 2000-08-05 | 2003-11-05 | Glaxo Group Ltd | Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos |
EP1324990B1 (en) | 2000-09-29 | 2014-10-29 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
WO2002067683A1 (en) | 2001-02-26 | 2002-09-06 | Merck & Co., Inc. | Hiv protease inhibitors supported on cation exchange resins for oral administration |
DE60220887T2 (de) | 2001-03-08 | 2008-02-28 | Glaxo Group Ltd., Greenford | Agonisten von beta-adrenorezeptoren |
US7045658B2 (en) | 2001-03-22 | 2006-05-16 | Glaxo Group Limited | Formailide derivatives as beta2-adrenoreceptor agonists |
KR100863659B1 (ko) | 2001-04-16 | 2008-10-15 | 미쓰비시 타나베 파마 코퍼레이션 | 질소-함유 헤테로시클릭 화합물 및 이를 포함하는 제약 조성물 |
WO2002088167A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
JP2005500290A (ja) | 2001-06-12 | 2005-01-06 | グラクソ グループ リミテッド | 抗炎症性の、17β−カルボチオアートアンドロスタン誘導体である17α複素環エステル |
WO2003000257A1 (fr) | 2001-06-26 | 2003-01-03 | Takeda Chemical Industries, Ltd. | Promoteur de production/secretion de la superfamille des tgf-$g(b) |
BRPI0212455B8 (pt) | 2001-09-14 | 2021-05-25 | Glaxo Group Ltd | composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo |
WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
AU2002353186A1 (en) | 2001-12-19 | 2003-06-30 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
AU2003202216A1 (en) | 2002-01-14 | 2003-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
AU2003214879B2 (en) | 2002-01-22 | 2008-02-07 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
FR2836915B1 (fr) | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
CA2477764A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US6903215B2 (en) | 2002-03-26 | 2005-06-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
ATE496620T1 (de) | 2002-04-11 | 2011-02-15 | Merck Sharp & Dohme | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren |
DE60318193T2 (de) | 2002-04-25 | 2008-12-04 | Glaxo Group Ltd., Greenford | Phenethanolaminderivate |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
WO2004002480A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
WO2004005229A1 (en) | 2002-07-08 | 2004-01-15 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
WO2004009017A2 (en) | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
EP1529045A2 (en) | 2002-08-09 | 2005-05-11 | Astra Zeneca AB | New compounds |
KR20050039846A (ko) | 2002-08-09 | 2005-04-29 | 아스트라제네카 에이비이 | 메타보트로픽 글루타메이트 수용체-5의 조절제로서의옥사디아졸 |
JP2006502134A (ja) | 2002-08-09 | 2006-01-19 | アストラゼネカ アクチボラグ | 代謝調節型グルタミン酸受容体において活性を有する化合物 |
US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
AU2003259747A1 (en) | 2002-08-21 | 2004-03-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
JP2006503108A (ja) | 2002-09-16 | 2006-01-26 | グラクソ グループ リミテッド | ピラゾロ[3,4−b]ピリジン化合物およびそれのホスホジエステラーゼ阻害薬としての使用 |
WO2004026248A2 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
ES2312843T3 (es) * | 2002-09-30 | 2009-03-01 | Bayer Healthcare Ag | Derivados de azolpirimidina condensados. |
GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
DE60315492T2 (de) | 2002-10-22 | 2008-04-24 | Glaxo Group Ltd., Greenford | Medizinisch verwendbare arylethanolamin verbindungen |
GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
US7442839B2 (en) | 2002-10-28 | 2008-10-28 | Glaxo Group Limited | Phenethanolamine derivative for the treatment of respiratory diseases |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
TW200519106A (en) * | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
JP2007500249A (ja) | 2003-06-13 | 2007-01-11 | ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ホスファチジルイノシトール3−キナーゼ阻害活性を有する化合物及びその使用方法 |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
GB0320197D0 (en) * | 2003-08-28 | 2003-10-01 | Novartis Ag | Organic compounds |
ATE494285T1 (de) | 2003-10-14 | 2011-01-15 | Glaxo Group Ltd | Muscarinische acetylcholin-rezeptor-antagonisten |
JP4110324B2 (ja) * | 2003-10-15 | 2008-07-02 | 宇部興産株式会社 | 新規インダゾール誘導体 |
WO2005044354A1 (en) | 2003-11-03 | 2005-05-19 | Glaxo Group Limited | A fluid dispensing device |
TW200524577A (en) | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
AU2004299277A1 (en) | 2003-12-19 | 2005-06-30 | Glaxo Group Limited | Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors |
WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
CA2555311A1 (en) | 2004-02-04 | 2005-08-18 | Neurosearch A/S | Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands |
KR20060130744A (ko) | 2004-03-16 | 2006-12-19 | 글락소 그룹 리미티드 | 피라졸로[3,4―b]피리딘 화합물 및 이의 pde4억제제로서의 용도 |
GB0405933D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
GB0405937D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
AR050902A1 (es) | 2004-04-27 | 2006-12-06 | Glaxo Group Ltd | Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion |
NZ551603A (en) | 2004-06-24 | 2010-11-26 | Incyte Corp | N-substituted piperidines and their use as pharmaceuticals |
WO2006000401A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Substituted oxazines as glucocorticoid receptor modulators |
WO2006000398A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
US20060013540A1 (en) * | 2004-07-19 | 2006-01-19 | Chao Zhang | Single fiber optical transceiver module |
WO2006135383A2 (en) | 2004-08-04 | 2006-12-21 | Myriad Genetics, Inc. | Indazoles |
GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
RU2391338C2 (ru) | 2004-10-19 | 2010-06-10 | Ф.Хоффманн-Ля Рош Аг | Производные хинолина |
US20060122210A1 (en) | 2004-11-18 | 2006-06-08 | Wenqing Yao | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same |
CA2589896A1 (en) | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Indole derivatives for use as ppar active compounds |
US20090124588A1 (en) | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
ATE517908T1 (de) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
EP1848428A4 (en) | 2005-02-18 | 2012-04-18 | Neurogen Corp | THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGS |
MX2007012056A (es) | 2005-03-31 | 2008-03-10 | Ronen Kahana | Creacion de aves de corral y otros animales resistentes a enfermedad viral. |
US20060264433A1 (en) | 2005-05-23 | 2006-11-23 | Backes Bradley J | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
TW200800946A (en) | 2005-08-15 | 2008-01-01 | Astrazeneca Ab | Substituted piperazines as metabotropic glutamate receptor antagonists |
US20070066624A1 (en) | 2005-08-16 | 2007-03-22 | Anormed, Inc. | Chemokine receptor binding compounds |
EP1995246A4 (en) | 2006-03-10 | 2010-11-17 | Ono Pharmaceutical Co | NITROGENATED HETEROCYCLIC DERIVATIVE AND MEDICAMENT WITH DERIVATIVE ACTIVE SUBSTANCE |
BRPI0709699A2 (pt) | 2006-03-29 | 2011-07-26 | Foldrx Pharmaceuticals Inc | inibiÇço da toxidez da alfa-sinucleina |
MX2008012482A (es) | 2006-03-31 | 2008-10-10 | Abbott Lab | Compuestos de indazol. |
CA2647391C (en) * | 2006-04-04 | 2015-12-29 | The Regents Of The University Of California | Kinase antagonists |
GB0608820D0 (en) | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
WO2008016123A1 (fr) | 2006-08-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | INHIBITEUR DE LA GSK-3β |
WO2008020229A2 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Antibacterial pyrrolecarboxamides |
MX2009002018A (es) | 2006-08-25 | 2009-03-05 | Abbott Lab | Derivados de indazol que inhiben vanilloide-1 potencial de receptor pasajero (trpv1) y usos de los mismos. |
US7948877B2 (en) * | 2006-09-07 | 2011-05-24 | Via Technologies, Inc. | Systems and methods for packet forward control |
JP2010504369A (ja) | 2006-09-25 | 2010-02-12 | ミュタビリス エス アー | 細菌ヘプトース合成の新規化学阻害剤、それらの調製方法および前記阻害剤の生物学的適用 |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
TWI454262B (zh) | 2006-11-02 | 2014-10-01 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
GB0701426D0 (en) | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
US8450348B2 (en) | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
JP2010116389A (ja) | 2008-10-17 | 2010-05-27 | Bayer Cropscience Ag | 殺虫性アリールピロリジン類 |
GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
JP5588339B2 (ja) | 2007-06-25 | 2014-09-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化学化合物 |
CA2697147A1 (en) | 2007-07-26 | 2009-02-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
US7893059B2 (en) | 2007-09-24 | 2011-02-22 | Genentech, Inc. | Thiazolopyrimidine PI3K inhibitor compounds and methods of use |
JP2009127226A (ja) * | 2007-11-21 | 2009-06-11 | Seiji Ohara | 温水プールに雪を落し込む手段を持つ融雪装置 |
CA2722427A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
JP5696037B2 (ja) | 2008-05-01 | 2015-04-08 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター |
EP2291373B1 (en) * | 2008-05-01 | 2013-09-11 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
JP5538365B2 (ja) * | 2008-05-01 | 2014-07-02 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤 |
WO2009147189A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
EP2300437B1 (en) | 2008-06-05 | 2013-11-20 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
EP2280946B1 (en) | 2008-06-05 | 2016-02-10 | Glaxo Group Limited | 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
EP2280959B1 (en) | 2008-06-05 | 2012-04-04 | Glaxo Group Limited | 4-amino-indazoles |
US10322469B2 (en) | 2008-06-11 | 2019-06-18 | Hamamatsu Photonics K.K. | Fusion bonding process for glass |
RU2539979C2 (ru) | 2008-07-25 | 2015-01-27 | Вайтаи Фармасьютиклз, Инк. | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 |
WO2010127237A2 (en) | 2009-04-30 | 2010-11-04 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US8245111B2 (en) * | 2008-12-09 | 2012-08-14 | Intel Corporation | Performing multi-bit error correction on a cache line |
US20110237633A1 (en) | 2008-12-11 | 2011-09-29 | Bijoy Panicker | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
US20120039905A1 (en) | 2009-01-13 | 2012-02-16 | The Babraham Institute | The Role of p110 delta Signaling in Morbidity and Lung Pathology Induced by Influenza Virus Infection |
EP2406255B1 (en) * | 2009-03-09 | 2015-04-29 | Glaxo Group Limited | 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases |
CA2759476C (en) * | 2009-04-30 | 2018-10-09 | Julie Nicole Hamblin | Novel compounds |
US8343959B2 (en) | 2009-04-30 | 2013-01-01 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
UA109255C2 (ru) | 2009-04-30 | 2015-08-10 | Берінгер Інгельхайм Інтернешнл Гмбх | Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1 |
UA107080C2 (uk) | 2009-04-30 | 2014-11-25 | Сполуки n-феніл(піперазиніл або гомопіперазиніл)бензолсульфонаміду або бензолсульфонілфеніл(піперазину або гомопіперазину), придатні для лікування захворювань, які реагують на модулювання рецептора 5-ht6 серотоніну | |
WO2010124845A1 (en) * | 2009-04-30 | 2010-11-04 | Bayer Cropscience Ag | Pesticidal arylpyrrolidines |
US20120238571A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Indazole derivatives as pi 3-kinase |
WO2011067364A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
EP2507223A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
US9102668B2 (en) | 2010-09-08 | 2015-08-11 | Glaxo Group Limited | Polymorphs and salts |
EP2614058B1 (en) | 2010-09-08 | 2015-07-08 | GlaxoSmithKline Intellectual Property Development Limited | POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE |
US9326987B2 (en) | 2010-09-08 | 2016-05-03 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
US10642898B1 (en) * | 2017-04-11 | 2020-05-05 | Northrop Grumman Systems Corporation | Three-dimensional graph |
-
2010
- 2010-04-28 CA CA2759476A patent/CA2759476C/en active Active
- 2010-04-28 MX MX2011011534A patent/MX2011011534A/es active IP Right Grant
- 2010-04-28 PL PL14194866T patent/PL2899191T3/pl unknown
- 2010-04-28 ES ES17182412T patent/ES2876933T3/es active Active
- 2010-04-28 EP EP17182412.1A patent/EP3260453B1/en active Active
- 2010-04-28 ES ES14194866.1T patent/ES2644724T3/es active Active
- 2010-04-28 MA MA34398A patent/MA33304B1/fr unknown
- 2010-04-28 JP JP2012507720A patent/JP5570589B2/ja active Active
- 2010-04-28 BR BRPI1016219A patent/BRPI1016219B8/pt active IP Right Grant
- 2010-04-28 ME MEP-2017-242A patent/ME02900B/me unknown
- 2010-04-28 UA UAA201112776A patent/UA101098C2/uk unknown
- 2010-04-28 TW TW99113559A patent/TWI466884B/zh not_active IP Right Cessation
- 2010-04-28 ME MEP-2015-22A patent/ME02053B/me unknown
- 2010-04-28 KR KR1020167032300A patent/KR101771193B1/ko active IP Right Grant
- 2010-04-28 WO PCT/EP2010/055666 patent/WO2010125082A1/en active Application Filing
- 2010-04-28 TW TW103127990A patent/TWI516487B/zh not_active IP Right Cessation
- 2010-04-28 TW TW104135940A patent/TWI562992B/zh not_active IP Right Cessation
- 2010-04-28 PT PT141948661T patent/PT2899191T/pt unknown
- 2010-04-28 PE PE2011001881A patent/PE20120321A1/es active IP Right Grant
- 2010-04-28 EA EA201190227A patent/EA021056B1/ru not_active IP Right Cessation
- 2010-04-28 SI SI201030873T patent/SI2424864T1/sl unknown
- 2010-04-28 JO JOP/2010/0132A patent/JO3025B1/ar active
- 2010-04-28 NZ NZ596071A patent/NZ596071A/en not_active IP Right Cessation
- 2010-04-28 PT PT107148926T patent/PT2424864E/pt unknown
- 2010-04-28 SG SG10201401881QA patent/SG10201401881QA/en unknown
- 2010-04-28 SI SI201031548T patent/SI2899191T1/sl unknown
- 2010-04-28 PL PL10714892T patent/PL2424864T3/pl unknown
- 2010-04-28 RS RS20171020A patent/RS56433B1/sr unknown
- 2010-04-28 US US13/266,254 patent/US20120046286A1/en not_active Abandoned
- 2010-04-28 AR ARP100101429A patent/AR076435A1/es active IP Right Grant
- 2010-04-28 MY MYPI2011005217A patent/MY160454A/en unknown
- 2010-04-28 UY UY0001032585A patent/UY32585A/es not_active Application Discontinuation
- 2010-04-28 EP EP10714892.6A patent/EP2424864B1/en active Active
- 2010-04-28 AU AU2010243613A patent/AU2010243613B2/en not_active Ceased
- 2010-04-28 LT LTEP14194866.1T patent/LT2899191T/lt unknown
- 2010-04-28 EP EP14194866.1A patent/EP2899191B1/en active Active
- 2010-04-28 HU HUE14194866A patent/HUE034724T2/hu unknown
- 2010-04-28 KR KR1020117028746A patent/KR101679642B1/ko active IP Right Grant
- 2010-04-28 US US12/768,775 patent/US8575162B2/en active Active
- 2010-04-28 DK DK10714892.6T patent/DK2424864T3/en active
- 2010-04-28 DK DK14194866.1T patent/DK2899191T3/da active
- 2010-04-28 CN CN201080030329.2A patent/CN102459253B/zh active Active
- 2010-04-28 SG SG2011077989A patent/SG175782A1/en unknown
- 2010-04-28 US US12/768,777 patent/US8580797B2/en active Active
- 2010-04-28 ES ES10714892T patent/ES2531274T3/es active Active
- 2010-04-28 RS RS20150107A patent/RS53830B1/en unknown
-
2011
- 2011-10-21 CO CO11141673A patent/CO6390057A2/es active IP Right Grant
- 2011-10-23 IL IL215803A patent/IL215803A/en active IP Right Grant
- 2011-10-26 DO DO2011000328A patent/DOP2011000328A/es unknown
- 2011-10-27 ZA ZA2011/07878A patent/ZA201107878B/en unknown
- 2011-10-28 CL CL2011002706A patent/CL2011002706A1/es unknown
- 2011-11-15 CR CR20110603A patent/CR20110603A/es unknown
-
2012
- 2012-07-04 HK HK12106543.5A patent/HK1165801A1/xx not_active IP Right Cessation
- 2012-10-02 US US13/633,320 patent/US8586590B2/en active Active
- 2012-10-02 US US13/633,348 patent/US8586583B2/en active Active
- 2012-10-02 US US13/633,230 patent/US8609657B2/en active Active
-
2013
- 2013-11-25 US US14/088,505 patent/US20140080830A1/en not_active Abandoned
-
2015
- 2015-02-16 HR HRP20150173TT patent/HRP20150173T1/hr unknown
- 2015-02-19 SM SM201500043T patent/SMT201500043B/xx unknown
- 2015-05-27 US US14/722,176 patent/US20150328226A1/en not_active Abandoned
- 2015-09-30 HK HK15109638.2A patent/HK1209102A1/xx not_active IP Right Cessation
-
2016
- 2016-08-02 US US15/225,962 patent/US20170015656A1/en not_active Abandoned
-
2017
- 2017-02-15 US US15/433,010 patent/US20170157136A1/en not_active Abandoned
- 2017-05-05 AR ARP170101175A patent/AR108388A2/es unknown
- 2017-09-27 HR HRP20171450TT patent/HRP20171450T1/hr unknown
- 2017-10-11 CY CY20171101063T patent/CY1119515T1/el unknown
-
2018
- 2018-05-16 US US15/980,778 patent/US20180325911A1/en not_active Abandoned
-
2019
- 2019-02-20 US US16/280,094 patent/US10383879B2/en active Active
- 2019-07-09 US US16/505,769 patent/US10624898B2/en active Active
-
2020
- 2020-03-12 US US16/816,311 patent/US10946025B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150173T1 (hr) | Oksazolom supstituirani indazoli kao inhibitori pi3-kinaze | |
JP2012525349A5 (hr) | ||
JP7204821B2 (ja) | キナーゼ阻害剤である複素環式アミド | |
CA2849169C (en) | Pyrazole carboxamides as janus kinase inhibitors | |
KR20170042595A (ko) | 의약으로서의 rip1 키나제 억제제로서의 헤테로시클릭 아미드 | |
HRP20201469T1 (hr) | Derivati tetrahidroizokinolina | |
HRP20170622T1 (hr) | Derivati piridinila i kondenziranog piridinil triazolona | |
JP2016523911A5 (hr) | ||
HRP20180546T1 (hr) | Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti | |
HRP20171913T1 (hr) | Aminopirimidinilni spojevi kao inhibitori jak | |
HRP20170112T1 (hr) | Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze | |
RU2021133444A (ru) | Производные бензимидазола в качестве модуляторов ror-гамма | |
JP2018519323A5 (hr) | ||
JP2016526576A5 (hr) | ||
RU2016102137A (ru) | Первичные карбоксамиды в качестве ингибиторов bik | |
JP2017530185A5 (hr) | ||
JP2020506946A5 (hr) | ||
JP2018512381A5 (hr) | ||
RU2019132212A (ru) | Селективные ингибиторы hdac6 | |
HRP20220096T1 (hr) | Inhibitori lizin specifične demetilaze-1 | |
UA122385C2 (uk) | Сульфамоїлариламіди та їх застосування як лікарських препаратів для лікування гепатиту b | |
AU2005245386A1 (en) | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer | |
RU2013145299A (ru) | Тиазолопиримидины | |
RU2018104868A (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
JP2016512515A5 (hr) |